|
ZNF345 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
5.95379967549547E-10 |
| Normal-vs-Stage3 |
5.60662627435704E-14 |
| Normal-vs-Stage4 |
1.93089988442807E-12 |
| Stage1-vs-Stage2 |
8.387400E-01 |
| Stage1-vs-Stage3 |
3.733400E-01 |
| Stage1-vs-Stage4 |
2.388100E-02 |
| Stage2-vs-Stage3 |
4.417600E-01 |
| Stage2-vs-Stage4 |
4.907900E-02 |
| Stage3-vs-Stage4 |
1.805630E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
6.87879999961005E-07 |
| Normal-vs-Asian |
2.38120000384257E-08 |
| Caucasian-vs-AfricanAmerican |
9.021600E-01 |
| Caucasian-vs-Asian |
7.661900E-02 |
| AfricanAmerican-vs-Asian |
2.751600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.10818037974059E-12 |
| Normal-vs-Female |
1.90147897427551E-12 |
| Male-vs-Female |
8.832200E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.90996132640475E-12 |
| Normal-vs-Age(41-60Yrs) |
5.55111512312578E-16 |
| Normal-vs-Age(61-80Yrs) |
1.64324109874769E-12 |
| Normal-vs-Age(81-100Yrs) |
3.965100E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.265400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.913160E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.785200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.833960E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.870400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.231400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.983700E-04 |
| Classical-VS-Follicular |
7.314400E-01 |
| Classical-VS-Other |
5.851000E-01 |
| Classical-VS-Normal |
4.9424020431843E-11 |
| Tall-VS-Follicular |
4.077100E-03 |
| Tall-VS-Other |
1.260770E-01 |
| Tall-VS-Normal |
1.0325074129014E-14 |
| Follicular-VS-Other |
3.845200E-01 |
| Follicular-VS-Normal |
8.04556421485358E-12 |
| Other-VS-Normal |
3.183800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.44089209850063E-16 |
| Normal-vs-N1 |
9.84000003700913E-09 |
| N0-vs-N1 |
9.941400E-01 |
|
|
